The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1541
February 26, 2018
View Complete Issue         Table of Contents 2019 
Haegarda - A Subcutaneous C1 Esterase Inhibitor for Prevention of Hereditary Angioedema
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Haegarda - A Subcutaneous C1 Esterase Inhibitor for Prevention of Hereditary Angioedema
February 26, 2018 (Issue: 1541)
The FDA has approved Haegarda (CSL Bering), a human plasma-derived C1 esterase inhibitor (C1INH), for prophylaxis against hereditary angioedema (HAE) attacks in adolescents and adults. Haegarda is the fourth C1INH to be approved by the FDA and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Haegarda - A Subcutaneous C1 Esterase Inhibitor for Prevention of Hereditary Angioedema
Article code: 1541d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.